CoChat

Targeting myeloid-derived suppressor cells for cancer immunotherapy

Liu, Yijun, Wei, Guowei, Cheng, Wesley A., Dong, Zhenyuan, Sun, Han, Lee, Vincent Y., Cha, Soung-Chul, Smith, D. Lynne, Kwak, Larry W., Qin, Hong · 2018 · Cancer Immunology, Immunotherapy
Cited by 102

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-018-2175-3

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 123

  1. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. https://doi.org/10.1038/nri2506 · DOI · Paper page
  2. Choi HS, Ha SY, Kim HM, Ahn SM, Kang MS, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kang ES (2016) The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget 7(7):7940–7951. https://doi.org/10.18632/oncotarget.6958 · DOI
  3. Chevalier MF, Trabanelli S, Racle J, Salome B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derre L (2017) ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest 127(8):2916–2929. https://doi.org/10.1172/JCI89717 · DOI · Paper page
  4. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40(11):2969–2975. https://doi.org/10.1002/eji.201040895 · DOI · Paper page
  5. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202(7):931–939. https://doi.org/10.1084/jem.20050715 · DOI · Paper page
  6. Serafini P, Mgebroff S, Noonan K, Borrello I (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68(13):5439–5449. https://doi.org/10.1158/0008-5472.CAN-07-6621 · DOI · Paper page
  7. Dai J, El Gazzar M, Li GY, Moorman JP, Yao ZQ (2015) Myeloid-derived suppressor cells: paradoxical roles in infection and immunity. J Innate Immun 7(2):116–126. https://doi.org/10.1159/000368233 · DOI
  8. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22(2):238–244. https://doi.org/10.1016/j.coi.2010.01.021 · DOI · Paper page
  9. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172(2):989–999 · DOI · Paper page
  10. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V (2010) Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40(1):22–35. https://doi.org/10.1002/eji.200939903 · DOI · Paper page
  11. Jordan KR, Kapoor P, Spongberg E, Tobin RP, Gao D, Borges VF, McCarter MD (2017) Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. Cancer Immunol Immunother 66(4):503–513. https://doi.org/10.1007/s00262-016-1953-z · DOI
  12. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V (2014) Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 1319:47–65. https://doi.org/10.1111/nyas.12469 · DOI · Paper page
  13. Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ (2014) Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 41(6):947–959. https://doi.org/10.1016/j.immuni.2014.10.020 · DOI · Paper page
  14. Pillay J, Tak T, Kamp VM, Koenderman L (2013) Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci 70(20):3813–3827. https://doi.org/10.1007/s00018-013-1286-4 · DOI · Paper page
  15. Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL (2011) In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 41(3):749–759. https://doi.org/10.1002/eji.201041069 · DOI · Paper page
  16. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70(1):68–77. https://doi.org/10.1158/0008-5472.CAN-09-2587 · DOI · Paper page
  17. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI (2009) Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 182(9):5693–5701. https://doi.org/10.4049/jimmunol.0900092 · DOI · Paper page
  18. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13(7):828–835. https://doi.org/10.1038/nm1609 · DOI · Paper page
  19. Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ (2011) Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol 46(2):156–164. https://doi.org/10.3109/00365521.2010.516450 · DOI · Paper page
  20. Li H, Han Y, Guo Q, Zhang M, Cao X (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182(1):240–249 · DOI · Paper page
  21. Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R (2012) Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 61(6):827–838. https://doi.org/10.1007/s00262-011-1143-y · DOI
  22. Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanislawek A, Polkowski W, Kurylcio A, Kleer C, Chang AE, Wicha M, Sabel M, Zou W, Kryczek I (2016) Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling. Cancer Res 76(11):3156–3165. https://doi.org/10.1158/0008-5472.CAN-15-2528 · DOI · Paper page
  23. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166(9):5398–5406 · DOI · Paper page
  24. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE (2009) Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 9(7–8):937–948. https://doi.org/10.1016/j.intimp.2009.03.021 · DOI
  25. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70(9):3526–3536. https://doi.org/10.1158/0008-5472.CAN-09-3278 · DOI · Paper page
  26. Waight JD, Hu Q, Miller A, Liu S, Abrams SI (2011) Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6(11):e27690. https://doi.org/10.1371/journal.pone.0027690 · DOI · Paper page
  27. Yen BL, Yen ML, Hsu PJ, Liu KJ, Wang CJ, Bai CH, Sytwu HK (2013) Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3. Stem Cell Rep 1(2):139–151. https://doi.org/10.1016/j.stemcr.2013.06.006 (eCollection 2013) · DOI · Paper page
  28. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rebe C, Ghiringhelli F (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120(2):457–471. https://doi.org/10.1172/JCI40483 · DOI · Paper page
  29. Diao J, Yang X, Song X, Chen S, He Y, Wang Q, Chen G, Luo C, Wu X, Zhang Y (2015) Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3. Med Oncol 32(2):453. https://doi.org/10.1007/s12032-014-0453-2 · DOI
  30. Hu X, Li B, Li X, Zhao X, Wan L, Lin G, Yu M, Wang J, Jiang X, Feng W, Qin Z, Yin B, Li Z (2014) Transmembrane TNF-alpha promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J Immunol 192(3):1320–1331. https://doi.org/10.4049/jimmunol.1203195 · DOI · Paper page
  31. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC (2008) Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14(5):408–419. https://doi.org/10.1016/j.ccr.2008.10.011 · DOI · Paper page
  32. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116(10):2777–2790. https://doi.org/10.1172/JCI28828 · DOI · Paper page
  33. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P (2003) IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 170(1):270–278 · DOI · Paper page
  34. Munera V, Popovic PJ, Bryk J, Pribis J, Caba D, Matta BM, Zenati M, Ochoa JB (2010) Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann Surg 251(1):120–126. https://doi.org/10.1097/SLA.0b013e3181bfda1c · DOI
  35. Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR (2010) Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116(25):5738–5747. https://doi.org/10.1182/blood-2010-06-287839 · DOI · Paper page
  36. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP (2007) Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110(2):624–631. https://doi.org/10.1182/blood-2007-01-065714 · DOI · Paper page
  37. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2(10):1096–1103 · DOI · Paper page
  38. Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, Sultmann H, Altevogt P, Umansky V, Momma S (2015) Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology. https://doi.org/10.1080/2162402X.2015.1008371 · DOI · Paper page
  39. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205(10):2235–2249. https://doi.org/10.1084/jem.20080132 · DOI · Paper page
  40. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181(7):4666–4675 · DOI · Paper page
  41. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, Kato M, Prevost-Blondel A, Thiery JP, Abastado JP (2011) Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 9(9):e1001162. https://doi.org/10.1371/journal.pbio.1001162 · DOI · Paper page
  42. Umansky V, Blattner C, Gebhardt C, Utikal J (2017) CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. Cancer Immunol Immunother 66(8):1015–1023. https://doi.org/10.1007/s00262-017-1988-9 · DOI
  43. Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salome B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclement C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derre L, Jandus C (2017) Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun 8(1):593. https://doi.org/10.1038/s41467-017-00678-2 · DOI · Paper page
  44. Younis RH, Han KL, Webb TJ (2016) Human head and neck squamous cell carcinoma-associated semaphorin 4D induces expansion of myeloid-derived suppressor cells. J Immunol 196(3):1419–1429. https://doi.org/10.4049/jimmunol.1501293 · DOI
  45. Wang T, Chu Z, Lin H, Jiang J, Zhou X, Liang X (2014) Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice. Mol Biol Rep 41(6):4069–4076. https://doi.org/10.1007/s11033-014-3276-5 · DOI
  46. Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K (2016) Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget 7(27):42698–42715. https://doi.org/10.18632/oncotarget.8311 · DOI
  47. Wu L, Yan C, Czader M, Foreman O, Blum JS, Kapur R, Du H (2012) Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 119(1):115–126. https://doi.org/10.1182/blood-2011-06-363093 · DOI · Paper page
  48. Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, Eruslanov EB, Zhang P, Tchou J, Zhang R, Conejo-Garcia JR (2017) Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov 7(1):72–85. https://doi.org/10.1158/2159-8290.CD-16-0502 · DOI · Paper page
  49. Liu YF, Chen YY, He YY, Wang JY, Yang JP, Zhong SL, Jiang N, Zhou P, Jiang H, Zhou J (2017) Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia. J Leukoc Biol 102(2):449–458. https://doi.org/10.1189/jlb.5MA1116-453RR · DOI
  50. Wang SH, Lu QY, Guo YH, Song YY, Liu PJ, Wang YC (2016) The blockage of Notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression. Eur J Cancer 68:90–105. https://doi.org/10.1016/j.ejca.2016.08.019 · DOI
  51. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 11(7):856–861. https://doi.org/10.1016/j.intimp.2011.01.030 · DOI · Paper page
  52. Abad C, Nobuta H, Li J, Kasai A, Yong WH, Waschek JA (2014) Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol 95(2):357–367. https://doi.org/10.1189/jlb.1012531 · DOI
  53. Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188(1):21–28. https://doi.org/10.4049/jimmunol.1101029 · DOI · Paper page
  54. Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282(16):11613–11617. https://doi.org/10.1074/jbc.R600038200 · DOI · Paper page
  55. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67(9):4507–4513. https://doi.org/10.1158/0008-5472.CAN-06-4174 · DOI · Paper page
  56. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P (2011) Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118(20):5498–5505. https://doi.org/10.1182/blood-2011-07-365825 · DOI · Paper page
  57. Inamoto S, Itatani Y, Yamamoto T, Minamiguchi S, Hirai H, Iwamoto M, Hasegawa S, Taketo MM, Sakai Y, Kawada K (2016) Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through the CCL15-CCR1 chemokine axis. Clin Cancer Res 22(2):492–501. https://doi.org/10.1158/1078-0432.CCR-15-0726 · DOI · Paper page
  58. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ, Patel NB, Guo Z, Ramamoorthy V, Tieu TN, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin EJ, Yao W, Pan X, Ding Z, Shi Y, Li L, Chang Q, Troncoso P, Logothetis CJ, McArthur MJ, Chin L, Wang YA, DePinho RA (2016) Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov 6(1):80–95. https://doi.org/10.1158/2159-8290.CD-15-0224 · DOI · Paper page
  59. Zhang H, Ye YL, Li MX, Ye SB, Huang WR, Cai TT, He J, Peng JY, Duan TH, Cui J, Zhang XS, Zhou FJ, Wang RF, Li J (2017) CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene 36(15):2095–2104. https://doi.org/10.1038/onc.2016.367 · DOI · Paper page
  60. Najjar YG, Rayman P, Jia X, Pavicic PG Jr, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, Diaz-Montero CM, Finke J (2017) Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1beta, IL8, CXCL5, and Mip-1alpha. Clin Cancer Res 23(9):2346–2355. https://doi.org/10.1158/1078-0432.CCR-15-1823 · DOI · Paper page
  61. Kusmartsev S, Gabrilovich DI (2003) Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 74(2):186–196 · DOI · Paper page
  62. Greifenberg V, Ribechini E, Rossner S, Lutz MB (2009) Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 39(10):2865–2876. https://doi.org/10.1002/eji.200939486 · DOI · Paper page
  63. Kusmartsev S, Gabrilovich DI (2005) STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174(8):4880–4891 · DOI · Paper page
  64. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111(8):4233–4244. https://doi.org/10.1182/blood-2007-07-099226 · DOI · Paper page
  65. Lechner MG, Liebertz DJ, Epstein AL (2010) Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185(4):2273–2284. https://doi.org/10.4049/jimmunol.1000901 · DOI · Paper page
  66. Yaddanapudi K, Rendon BE, Lamont G, Kim EJ, Al Rayyan N, Richie J, Albeituni S, Waigel S, Wise A, Mitchell RA (2016) MIF is necessary for late-stage melanoma patient MDSC immune suppression and differentiation. Cancer Immunol Res 4(2):101–112. https://doi.org/10.1158/2326-6066.CIR-15-0070-T · DOI
  67. Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C (2010) Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 123(Pt 10):1603–1611. https://doi.org/10.1242/jcs.064386 · DOI · Paper page
  68. Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, Cheng Z, Shah SV, Wang GJ, Zhang L, Grizzle WE, Mobley J, Zhang HG (2009) Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 124(11):2621–2633. https://doi.org/10.1002/ijc.24249 · DOI · Paper page
  69. Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi PP, Kufe D, Rosenblatt J, Avigan D (2017) MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 129(13):1791–1801. https://doi.org/10.1182/blood-2016-07-730614 · DOI · Paper page
  70. Liu Y, Munoz N, Tsai AC, Logan TM, Ma T (2017) Metabolic reconfiguration supports reacquisition of primitive phenotype in human mesenchymal stem cell aggregates. Stem Cells 35(2):398–410. https://doi.org/10.1002/stem.2510 · DOI
  71. Tsai AC, Liu Y, Yuan X, Ma T (2015) Compaction, fusion, and functional activation of three-dimensional human mesenchymal stem cell aggregate. Tissue Eng Part A 21(9–10):1705–1719. https://doi.org/10.1089/ten.TEA.2014.0314 · DOI · Paper page
  72. Liu Y, Ma T (2015) Metabolic regulation of mesenchymal stem cell in expansion and therapeutic application. Biotechnol Prog 31(2):468–481. https://doi.org/10.1002/btpr.2034 · DOI
  73. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L (1995) A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182(6):1683–1693 · DOI · Paper page
  74. Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, Sanchez-Garcia FJ (2016) Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol 7:52. https://doi.org/10.3389/fimmu.2016.00052 · DOI · Paper page
  75. Bronte V (2014) Tumor cells hijack macrophages via lactic acid. Immunol Cell Biol 92(8):647–649. https://doi.org/10.1038/icb.2014.67 · DOI
  76. Hammami I, Chen J, Murschel F, Bronte V, De Crescenzo G, Jolicoeur M (2012) Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biol 13:18. https://doi.org/10.1186/1471-2121-13-18 · DOI · Paper page
  77. Jian SL, Chen WW, Su YC, Su YW, Chuang TH, Hsu SC, Huang LR (2017) Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell Death Dis 8(5):e2779. https://doi.org/10.1038/cddis.2017.192 · DOI · Paper page
  78. Wu T, Zhao Y, Wang H, Li Y, Shao L, Wang R, Lu J, Yang Z, Wang J, Zhao Y (2016) mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors. Sci Rep 6:20250. https://doi.org/10.1038/srep20250 · DOI
  79. Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, Valle LD, Trillo-Tinoco J, Maj T, Zou W, Rodriguez PC, Ochoa AC (2015) Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 3(11):1236–1247. https://doi.org/10.1158/2326-6066.CIR-15-0036 · DOI · Paper page
  80. Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, Sanchez MD, Dean MJ, Rodriguez PC, Ochoa AC (2017) Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology 6(10):e1344804. https://doi.org/10.1080/2162402X.2017.1344804 · DOI · Paper page
  81. Roda JM, Parihar R, Carson WE III (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175(3):1619–1627 · DOI
  82. Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey BD, Kao C (2011) The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 133(2):221–238. https://doi.org/10.1111/j.1365-2567.2011.03429.x · DOI
  83. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63(15):4441–4449
  84. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66(18):9299–9307. https://doi.org/10.1158/0008-5472.CAN-06-1690 · DOI · Paper page
  85. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI (2007) Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 67(22):11021–11028. https://doi.org/10.1158/0008-5472.CAN-07-2593 · DOI · Paper page
  86. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D (2013) Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 62(5):909–918. https://doi.org/10.1007/s00262-013-1396-8 · DOI · Paper page
  87. Bill MA, Fuchs JR, Li C, Yui J, Bakan C, Benson DM Jr, Schwartz EB, Abdelhamid D, Lin J, Hoyt DG, Fossey SL, Young GS, Carson WE III, Li PK, Lesinski GB (2010) The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 9:165. https://doi.org/10.1186/1476-4598-9-165 · DOI · Paper page
  88. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, Liu A, Wang TC, Yang CS (2012) Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) 5(2):205–215. https://doi.org/10.1158/1940-6207.CAPR-11-0247 · DOI · Paper page
  89. Kortylewski M, Moreira D (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66(8):979–988. https://doi.org/10.1007/s00262-017-1966-2 · DOI
  90. Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, Jones J, D’Apuzzo M, Forman S, Kortylewski M (2015) TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res 21(16):3771–3782. https://doi.org/10.1158/1078-0432.CCR-14-3145 · DOI · Paper page
  91. Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, Su Z, Kaliberov S, Heiser A, Rosser C, Dahm P, Siemann D, Vieweg J (2008) Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 181(1):346–353 · DOI · Paper page
  92. Limagne E, Euvrard R, Thibaudin M, Rebe C, Derangere V, Chevriaux A, Boidot R, Vegran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F (2016) Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res 76(18):5241–5252. https://doi.org/10.1158/0008-5472.CAN-15-3164 · DOI · Paper page
  93. Koinis F, Vetsika EK, Aggouraki D, Skalidaki E, Koutoulaki A, Gkioulmpasani M, Georgoulias V, Kotsakis A (2016) Effect of first-line treatment on myeloid-derived suppressor cells’ subpopulations in the peripheral blood of patients with non-small cell lung cancer. J Thorac Oncol 11(8):1263–1272. https://doi.org/10.1016/j.jtho.2016.04.026 · DOI
  94. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP (2010) COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 10:464. https://doi.org/10.1186/1471-2407-10-464 · DOI · Paper page
  95. Albu DI, Wang Z, Huang KC, Wu J, Twine N, Leacu S, Ingersoll C, Parent L, Lee W, Liu D, Wright-Michaud R, Kumar N, Kuznetsov G, Chen Q, Zheng W, Nomoto K, Woodall-Jappe M, Bao X (2017) EP4 antagonism by E7046 diminishes myeloid immunosuppression and synergizes with Treg-reducing IL-2-diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology 6(8):e1338239. https://doi.org/10.1080/2162402X.2017.1338239 · DOI · Paper page
  96. Hong DS, Parikh A, Shapiro G, Varga A, Naing A, Meric-Bernstam F, Reyderman L, Bao X, Binder TA, Ren M, Siu A, Xu L, Liu M, Dayal S, Bhagawati-Prasad V, Tchakov I, Owa T, Ooi CE, Marabelle A (2018) Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression. In: 2018 ASCO-SITC clinical immuno-oncology symposium. J Clin Oncol 36 (suppl 5S; Abstract 49) · doi:10.1200/jco.2018.36.5_suppl.49
  97. Evans EE, Jonason AS Jr, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, Fisher TL, Bowers WJ, Paris M, Smith ES, Zauderer M (2015) Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol Res 3(6):689–701. https://doi.org/10.1158/2326-6066.CIR-14-0171 · DOI
  98. Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK (2016) Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 22(4):827–836. https://doi.org/10.1158/1078-0432.CCR-15-0431 · DOI
  99. Wang-Gillam A, Noel MS, Sleijfer S, Jung H, Lohr L, Zhao N, Miao S, Potarca A, Charo I, Bekker P, Schall TJ (2016) The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients. In: ASCO annual meeting 2016. J Clin Oncol 34 (suppl 15; Abstract e15743) · doi:10.1200/jco.2016.34.15_suppl.e15743
  100. Linehan D, Noel MS, Hezel AF, Wang-Gillam A, Eskens F, Sleijfer S, Desar IME, Erdkamp F, Wilmink J, Diehl J, Potarca A, Zhao N, Miao S, Deng J, Hillson J, Bekker P, Schall TJ, Singh R (2018) Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: correlation with blood monocyte counts. In: 2018 ASCO-SITC clinical immuno-oncology symposium. J Clin Oncol 36 (suppl 5S; Abstract 92) · DOI · Paper page
  101. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203(12):2691–2702. https://doi.org/10.1084/jem.20061104 · DOI · Paper page
  102. Wesolowski R, Markowitz J, Carson WE III (2013) Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer 1:10. https://doi.org/10.1186/2051-1426-1-10 · DOI · Paper page
  103. Hassel JC, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, Halama N, Dimitrakopoulou-Strauss A, Haefeli WE, Jager D, Enk A, Utikal J, Umansky V (2017) Tadalafil has biologic activity in human melanoma. Results of a pilot trial with tadalafil in patients with metastatic melanoma (TaMe). Oncoimmunology 6(9):e1326440. https://doi.org/10.1080/2162402X.2017.1326440 · DOI
  104. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, Bronte V (2005) Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 102(11):4185–4190. https://doi.org/10.1073/pnas.0409783102 · DOI · Paper page
  105. Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, Zhang C, Yue D, Qin G, Zhang T, Li F, Chen X, Ping Y, Wang D, Gao Q, He Q, Huang L, Li H, Huang J, Zhao X, Xue W, Sun Z, Lu J, Yu JJ, Zhao J, Zhang B, Zhang Y (2018) Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res 78(7):1779–1791. https://doi.org/10.1158/0008-5472.CAN-17-2460 · DOI · Paper page
  106. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella VJ, McGovern K, Kutok JL, Wolchok JD, Merghoub T (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539(7629):443–447. https://doi.org/10.1038/nature20554 · DOI · Paper page
  107. Pachter JA, Weaver DT (2018) Effect of dual PI3K-δ,γ inhibitor duvelisib on immunosuppressive Tregs and myeloid cells to enhance efficacy of checkpoint and co-stimulatory antibodies in a B cell lymphoma model. In: 2018 ASCO-SITC clinical immuno-oncology symposium. J Clin Oncol 36 (suppl 5S; Abstract 33) · doi:10.1200/jco.2018.36.5_suppl.33
  108. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11(18):6713–6721. https://doi.org/10.1158/1078-0432.CCR-05-0883 · DOI · Paper page
  109. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70(8):3052–3061. https://doi.org/10.1158/0008-5472.CAN-09-3690 · DOI · Paper page
  110. Rong Y, Yuan CH, Qu Z, Zhou H, Guan Q, Yang N, Leng XH, Bu L, Wu K, Wang FB (2016) Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. Sci Rep 6:23824. https://doi.org/10.1038/srep23824 · DOI
  111. Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, Hubert A, Baniyash M (2014) Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res 74(21):6022–6035. https://doi.org/10.1158/0008-5472.CAN-14-0657 · DOI · Paper page
  112. Wang Z, Liu Y, Zhang Y, Shang Y, Gao Q (2016) MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. Oncotarget 7(4):4760–4769. https://doi.org/10.18632/oncotarget.6734 · DOI
  113. Isherwood J, Arshad A, Chung W, Runau F, Cooke J, Pollard C, Thompson J, Metcalfe M, Dennison A (2017) Parenteral omega 3 significantly reduces myeloid-derived suppressor cells in palliative pancreatic patients receiving gemcitabine and intravenous omega 3 compared to patients receiving gemcitabine only treatment. In: ESPEN congress 2017. Clin Nutr 36 (suppl; Abstract P107) · doi:10.1016/s0261-5614(17)30520-4
  114. Takeuchi S, Baghdadi M, Tsuchikawa T, Wada H, Nakamura T, Abe H, Nakanishi S, Usui Y, Higuchi K, Takahashi M, Inoko K, Sato S, Takano H, Shichinohe T, Seino K, Hirano S (2015) Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer. Cancer Res 75(13):2629–2640. https://doi.org/10.1158/0008-5472.CAN-14-2921 · DOI · Paper page
  115. Heine A, Schilling J, Grunwald B, Kruger A, Gevensleben H, Held SA, Garbi N, Kurts C, Brossart P, Knolle P, Diehl L, Hochst B (2016) The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib. Cancer Immunol Immunother 65(3):273–282. https://doi.org/10.1007/s00262-015-1790-5 · DOI
  116. Seliger B, Giersberg C, Staehler MD (2011) Modulation of immune cell subpopulations in renal cell carcinoma patients by sunitinib. In: 2011 ASCO/ASTRO/SUO genitourinary cancers symposium. J Clin Oncol 29 (suppl 7: Abstract 395) · DOI
  117. Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE III (2015) The Raf kinase inhibitor sorafenib inhibits JAK-STAT signal transduction in human immune cells. J Immunol 195(5):1995–2005. https://doi.org/10.4049/jimmunol.1400084 · DOI
  118. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Gotz M, Guillaume P, Dohner H, Bunjes D, Schmitt M (2008) Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 36(10):1297–1308. https://doi.org/10.1016/j.exphem.2008.05.002 · DOI
  119. Guo C, Hu F, Yi H, Feng Z, Li C, Shi L, Li Y, Liu H, Yu X, Wang H, Li J, Li Z, Wang XY (2016) Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis 75(1):278–285. https://doi.org/10.1136/annrheumdis-2014-205508 · DOI · Paper page
  120. Hurez V, Daniel BJ, Sun L, Liu AJ, Ludwig SM, Kious MJ, Thibodeaux SR, Pandeswara S, Murthy K, Livi CB, Wall S, Brumlik MJ, Shin T, Zhang B, Curiel TJ (2012) Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 72(8):2089–2099. https://doi.org/10.1158/0008-5472.CAN-11-3019 · DOI · Paper page
  121. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE (2008) Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 83(1):64–70. https://doi.org/10.1189/jlb.0407247 · DOI · Paper page
  122. Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, Kumar P, Gabrilovich DI (2017) Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin Cancer Res 23(12):2942–2950. https://doi.org/10.1158/1078-0432.CCR-16-1784 · DOI · Paper page
  123. Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW (2014) Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 20(6):676–681. https://doi.org/10.1038/nm.3560 · DOI · Paper page

Cited by

See all 102

Metadata

Authors
Liu, Y., Wei, G., Cheng, W. A., Dong, Z., Sun, H., Lee, V. Y., Cha, S.-C., Smith, D. L., Kwak, L. W., & Qin, H.
Venue
Cancer Immunology, Immunotherapy
Published
2018-05-31
Volume
67
Issue
8
Pages
1181-1195
ISSN
  • 0340-7004
  • 1432-0851
Cited by
102
References
19
Language
en
Licence
Funders
  • U.S. Department of Defense (W81XWH-14-PRCRP-CDA)
  • Leukemia and Lymphoma Society (0855-14)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.